SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending downwards following news of a planned bond sale to fund AI investments, sparking concerns about increased spending and potential impact on shareholder value. The community is debating whether the dip presents a buying opportunity, considering the company's fundamentals and long-term growth potential amid the AI push. Some investors are drawing comparisons to past overspending concerns while others see it as a strategic move for future growth.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit's stock is trending as investors anticipate upcoming earnings, with the community closely watching key metrics like user growth and advertising revenue. Bullish sentiment is fueled by analysts setting higher price targets and highlighting potential from AI and data licensing deals. Short interest is also a key factor being watched.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies behind the OG meme, fueled by a desire to reclaim internet culture. Discussions center on achieving the #1 spot and bringing back the spirit of the 2021 meme era. The community emphasizes belief, teamwork, and rejecting traditional financial analysis in favor of cultural relevance.

Cambium Networks Corp. is a holding company, which engages in the provision of wireless broadband networking infrastructure solutions for network operators. Its products include point-to-point, enterprise Wi-Fi and switching, CCTV, software, and point-to multipoint. The company was founded in 2011 and is headquartered in Hoffman Estates, IL.

Cambium Networks Corp

CMBM is trending due to excitement around its integration with Starlink, with retail traders discussing a potential short squeeze and high trading volume. Community members are debating resistance levels and potential price targets, while also weighing the company's fundamentals and potential for further gains. The stock's volatile price action and significant overnight gains have fueled speculation about its short-term trajectory.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle ($CMG) is trending due to a significant drop following a lowered sales outlook, sparking discussions about consumer spending and the company's value proposition. Community members are debating whether the dip is a buying opportunity or a sign of deeper issues with the brand, citing concerns about pricing, portion sizes, and competition in the fast-casual dining sector.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors anticipate earnings, with community members pointing to the stock's recent strength and potential AI-driven growth. Discussions include Google's partnership with Reliance Jio in India and its increased capital expenditure outlook, with some expecting the stock to test the $300 level. Bullish sentiment is fueled by positive analyst ratings and expectations of a strong quarter.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as it approaches earnings, fueled by optimism around its AI and cloud services. The community is actively discussing the stock's impressive run and debating whether it's overbought, while also noting Google's expansion into new sectors like nuclear energy.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific ($CORZ) is trending as shareholders prepare to vote on a proposed merger with CoreWeave ($CRWV), with many in the community expressing concerns that the deal undervalues $CORZ, particularly given its AI infrastructure potential. Some investors believe that rejecting the deal could lead to a higher valuation for $CORZ as a standalone entity or attract a better offer, while others worry about the company's future prospects without the merger.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

EBS is trending due to raised FY25 EBITDA guidance, sparking optimism about the company's future profitability. The community is discussing the potential for a significant stock re-rating and a short squeeze, with some highlighting the low P/E ratio relative to the broader market. Discussions also involve potential catalysts like government appropriations and debt refinancing.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands, herbicides under the Authority, Boral, Centium, Command, and Gamit brands, insecticides under the Talstar and Hero brands, flutriafol-based fungicides, and bionematicides under the Quartzo and Presence brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC Corp. is experiencing a significant drop, driven by a dividend cut and lowered full-year earnings expectations, prompting community concern about potential debt issues and bankruptcy. Despite the downturn, some investors view the stock as oversold, anticipating a turnaround as the company focuses on debt reduction. Community members are actively discussing entry points, potential rebound levels, and whether the steep decline is an overreaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...

Here's Why Alto Neuroscience, Inc. (ANRO) is a Great Momentum Stock to Buy

Does Alto Neuroscience, Inc. (ANRO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Can Alto Neuroscience, Inc. (ANRO) Climb 27.45% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 27.5% upside potential for Alto Neuroscience, Inc. (ANRO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Shares of Alto Neuroscience (ANRO) soared 54% on Friday afternoon after the company announced that the U.S. Food and Drug Administration granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia.Cognitive impairment is a core and disabling feature of Schizophrenia, a serious, disabling mental illness affecting thought, perception, and behavior. According to Alto, there are currently no approved treatments for cognitive impairment associated with schizophrenia.FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. A company, whose drug has a Fast Track designation, may be eligible for more frequent meetings with the FDA to discuss the drug’s development plan, as well as for accelerated approval and priority review, subject to the fulfillment of relevant criteria.ALTO-101 is an inhibitor of the PDE4 enzyme that plays a key role in the brain by breaking down a molecule fundamental to learning and memory. By inhibiting the enzyme, the drug seeks to increase the levels of the molecule believed to improve cognitive function.Alto CEO Amit Etkin <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.altoneuroscience.com/news/news-details/2025/Alto-Neuroscience-Receives-FDA-Fast-Track-Designation-for-ALTO-101-for-the-Treatment-of-Cognitive-Impairment-Associated-with-Schizophrenia/default.aspx">termed</a> the designation a significant milestone. “Our Phase 1 data, which demonstrated significant and clinically relevant effects of ALTO-101 on both EEG measures and cognitive performance in healthy subjects, provides strong validation for its mechanism,” he added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ANRO">ANRO stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:579/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_03_at_12_01_14_PM_png_f2a3fffa4a.webp" alt="ANRO's Sentiment Meter and Message Volume as of 12 p.m. ET on Oct. 03, 2025 | Source: Stocktwits" width="579" height="59"><figcaption>ANRO's Sentiment Meter and Message Volume as of 12 p.m. ET on Oct. 03, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user highlighted the company’s strong pipeline. Alto is seeking to develop treatments for mental health conditions, including bipolar depression, major depressive disorder, treatment-resistant depression (TRD), and schizophrenia.<stembedurl>https://stocktwits.com/Ccperk/message/630959482</stembedurl>Another user believes the FDA's Fast Track designation is the icing on the cake.<stembedurl>https://stocktwits.com/Ccperk/message/630949029</stembedurl>ANRO stock is up by 61% this year but down by 33% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-reportedly-eyes-door-redesign-to-alleviate-safety-concerns-report/chCuVXzR3QQ">Rivian Reportedly Eyes Door Redesign To Alleviate Safety Concerns: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alto Neuroscience logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug

FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.

Equity

FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.


Alto Neuroscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ANRO

Alto Neuroscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ANRO Alto Neuroscience, Inc. Sued for Securities Law Violations...

1 ‘Strong Buy’ Penny Stock With 270% Upside to Load Up On in March

Alto Neuroscience represents a high-risk, high-reward opportunity.

Alto Neuroscience Inc. has struggled recently, with shares losing more than 12% over the past week, extending a decline that began in late October following disappointing Phase 2&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anro-stock-crashes-premarket-after-drug-trial-fails/cJ2L0NwReH">results</a> for its major depressive disorder (MDD) treatment, ALTO-100.&nbsp;Despite the stock sliding over 34% this year, it has not lost appeal among retail traders as Alto's follower count on Stocktwits has surged 44.6% in the past week.&nbsp;Over the last year, its retail following on the platform has grown by an astonishing 876%, suggesting that traders remain interested in the company's long-term prospects.Alto is developing treatments for central nervous system diseases and has positioned its biomarker-driven approach as a differentiator in psychiatric drug development.&nbsp;While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials.&nbsp;Last month, Alto announced that a planned interim analysis of the trial had a favorable outcome, prompting the company to expand the study by approximately 50 biomarker-positive patients. Topline results from the trial are expected in mid-2026.&nbsp;The company also secured a U.S. patent for ALTO-300, covering its use as an adjunctive treatment for MDD patients who have not responded adequately to traditional antidepressants.&nbsp;The patent also includes methods for identifying eligible patients using EEG-based biomarker selection, which Alto sees as a key advantage in developing more targeted psychiatric treatments.<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ANRO_sentiment_and_message_volume_as_of_Feb_28_3028c3e1a2.png" alt="ANRO sentiment and message volume as of Feb 28.png" width="1316" height="316"><figcaption>ANRO sentiment and message volume as of Feb 28 vs a week ago | source: Stocktwits</figcaption></figure>Retail traders on Stocktwits have pointed to several potential catalysts, including reports that Jefferies sees a 500% upside for the stock.&nbsp;Some investors have also highlighted Alto's financial position, noting that the company is trading near 40% of its cash value while holding two Phase 3-ready assets and no debt.<stembedurl>https://stocktwits.com/Eternallybullish1988/message/606427653</stembedurl><stembedurl>https://stocktwits.com/BossTrade/message/606325236</stembedurl>Jones Research maintained a 'Buy' rating with an $18 price target in December, arguing that the market reaction to ALTO-100's failure was overdone.&nbsp;Last week, Alto said it would participate in a series of upcoming industry conferences in March, including the TD Cowen 45th Annual Health Care Conference, Leerink's Global Healthcare Conference, and the Stifel 2025 Virtual CNS Forum.&nbsp;With attention now focused on the ALTO-300 trial and upcoming investor events, retail investors will be hoping market sentiment around the stock tilts back into the bullish zone.Alto stock is rated ‘buy’ among six out of seven analysts covering the stock on Wall Street, with one rating ‘hold’, according to Koyfin data.Short interest, meanwhile, has edged down from 15.1% at the start of this year to 14.7% as of the end of last week.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock

While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials. 

Why Micro-Cap Alto Neuroscience's Retail Following On Stocktwits Surged Nearly 45% Last Week

While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials. 


Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the...

Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple...

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

ANRO
Alto Neuroscience Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ANRO News

ANROAlto Neuroscience Inc.